Lowest-Rated StocksLowest-RatedNASDAQ:FATE Fate Therapeutics (FATE) Stock Forecast, Price & News $5.30 -0.17 (-3.11%) (As of 06/8/2023 ET) Add Compare Share Share Today's Range$5.05▼$5.4750-Day Range$4.89▼$6.5952-Week Range$4.02▼$37.13Volume2.67 million shsAverage Volume3.18 million shsMarket Capitalization$521.41 millionP/E RatioN/ADividend YieldN/APrice Target$15.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Fate Therapeutics MarketRank™ ForecastAnalyst RatingHold2.14 Rating ScoreUpside/Downside192.5% Upside$15.50 Price TargetShort InterestBearish31.55% of Float Sold ShortDividend StrengthN/ASustainability-0.70Upright™ Environmental ScoreNews Sentiment0.42Based on 8 Articles This WeekInsider TradingAcquiring Shares$274,000 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($1.92) to ($2.08) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.75 out of 5 starsMedical Sector754th out of 986 stocksBiological Products, Except Diagnostic Industry120th out of 158 stocks 3.1 Analyst's Opinion Consensus RatingFate Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.14, and is based on 5 buy ratings, 14 hold ratings, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.50, Fate Therapeutics has a forecasted upside of 192.5% from its current price of $5.30.Amount of Analyst CoverageFate Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted31.55% of the float of Fate Therapeutics has been sold short.Short Interest Ratio / Days to CoverFate Therapeutics has a short interest ratio ("days to cover") of 10.8, which indicates bearish sentiment.Change versus previous monthShort interest in Fate Therapeutics has recently increased by 3.74%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldFate Therapeutics does not currently pay a dividend.Dividend GrowthFate Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreFate Therapeutics has received a 75.52% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health", "Preclinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Fate Therapeutics is -0.70. Previous Next 1.9 News and Social Media Coverage News SentimentFate Therapeutics has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Fate Therapeutics this week, compared to 5 articles on an average week.Search InterestOnly 3 people have searched for FATE on MarketBeat in the last 30 days. This is a decrease of -70% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Fate Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Fate Therapeutics insiders have bought 1,547.13% more of their company's stock than they have sold. Specifically, they have bought $274,000.00 in company stock and sold $16,635.00 in company stock.Percentage Held by InsidersOnly 5.04% of the stock of Fate Therapeutics is held by insiders. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Fate Therapeutics are expected to decrease in the coming year, from ($1.92) to ($2.08) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Fate Therapeutics is -2.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Fate Therapeutics is -2.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFate Therapeutics has a P/B Ratio of 1.06. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Fate Therapeutics (NASDAQ:FATE) StockFate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma and FT522, to treat lymphoma and autoimmune disorders; and CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.Read More Receive FATE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fate Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address FATE Stock News HeadlinesJune 7, 2023 | finance.yahoo.comWhy Is Axsome (AXSM) Down 2.5% Since Last Earnings Report?June 5, 2023 | finance.yahoo.comMonoclonal Antibodies Clinical Trial Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 180+ Companies Working in the DomainJune 9, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...June 5, 2023 | americanbankingnews.comFate Therapeutics, Inc. (NASDAQ:FATE) Receives $13.19 Consensus PT from BrokeragesJune 4, 2023 | finance.yahoo.comFate Therapeutics, Inc.'s (NASDAQ:FATE) Low P/S No Reason For ExcitementJune 2, 2023 | finance.yahoo.comFate Therapeutics (FATE) Down 17.8% Since Last Earnings Report: Can It Rebound?May 31, 2023 | finance.yahoo.comFate Therapeutics to Present at Upcoming June Investor ConferencesMay 25, 2023 | americanbankingnews.comFate Therapeutics (NASDAQ:FATE) Trading Up 6.7%June 9, 2023 | Behind the Markets (Ad)[Strong Buy Alert] Is this laser stock in your portfolio?🚨 [Strong Buy Alert] Is this laser stock in your portfolio? There are very few opportunities like this in today's bear market... But our analysts identified a tiny defense company landing billions of dollars in contracts every year.May 23, 2023 | msn.comFate Therapeutics: The Future Remains CloudyMay 16, 2023 | marketwatch.comNatural Killer Cells Therapeutics Market Analysis 2023-2030May 11, 2023 | americanbankingnews.comFate Therapeutics, Inc. (NASDAQ:FATE) Receives $13.19 Consensus Target Price from AnalystsMay 9, 2023 | americanbankingnews.comAnalysts Offer Predictions for Fate Therapeutics, Inc.'s Q2 2023 Earnings (NASDAQ:FATE)May 9, 2023 | americanbankingnews.comQ2 2023 Earnings Estimate for Fate Therapeutics, Inc. (NASDAQ:FATE) Issued By WedbushMay 8, 2023 | markets.businessinsider.comGrabar Law Office Investigates Claims on Behalf of Shareholders of Fate Therapeutics, Inc. (FATE)May 8, 2023 | finance.yahoo.comBroker Revenue Forecasts For Fate Therapeutics, Inc. (NASDAQ:FATE) Are Surging HigherMay 8, 2023 | americanbankingnews.comFate Therapeutics (NASDAQ:FATE) Given New $5.00 Price Target at Stifel NicolausMay 6, 2023 | msn.comHC Wainwright & Co. Reiterates Fate Therapeutics (FATE) Neutral RecommendationMay 5, 2023 | msn.comStifel Maintains Fate Therapeutics (FATE) Hold RecommendationMay 5, 2023 | msn.comCantor Fitzgerald Maintains Fate Therapeutics (FATE) Neutral RecommendationMay 5, 2023 | markets.businessinsider.comH.C. Wainwright Remains a Hold on Fate Therapeutics (FATE)May 4, 2023 | finance.yahoo.comQ1 2023 Fate Therapeutics Inc Earnings CallMay 4, 2023 | finance.yahoo.comFATE Incurs Narrower-Than-Expected Q1 Loss on Lower ExpensesMay 4, 2023 | americanbankingnews.comCantor Fitzgerald Trims Fate Therapeutics (NASDAQ:FATE) Target Price to $5.00May 3, 2023 | markets.businessinsider.comFate Therapeutics (FATE) Gets a Buy from Mizuho SecuritiesMay 3, 2023 | msn.comFate Therapeutics: Q1 Earnings InsightsMay 3, 2023 | finance.yahoo.comFate Therapeutics (FATE) Upgraded to Buy: Here's What You Should KnowSee More Headlines FATE Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FATE Company Calendar Last Earnings5/03/2023Today6/08/2023Next Earnings (Estimated)8/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:FATE CUSIPN/A CIK1434316 Webwww.fatetherapeutics.com Phone(858) 875-1800FaxN/AEmployees551Year FoundedN/APrice Target and Rating Average Stock Price Forecast$15.50 High Stock Price Forecast$65.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+201.0%Consensus RatingHold Rating Score (0-4)2.14 Research Coverage21 Analysts Profitability EPS (Most Recent Fiscal Year)($2.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-281,720,000.00 Net Margins-171.64% Pretax Margin-171.64% Return on Equity-45.62% Return on Assets-32.49% Debt Debt-to-Equity RatioN/A Current Ratio9.00 Quick Ratio9.00 Sales & Book Value Annual Sales$96.30 million Price / Sales5.26 Cash FlowN/A Price / Cash FlowN/A Book Value$4.98 per share Price / Book1.03Miscellaneous Outstanding Shares98,380,000Free Float93,425,000Market Cap$506.66 million OptionableOptionable Beta1.49 Key ExecutivesMr. J. Scott Wolchko (Age 53)Founder, CEO, Pres & Director Comp: $645kMr. Edward J. Dulac III (Age 47)Chief Financial Officer Comp: $455kMs. Cindy R. Tahl (Age 50)Gen. Counsel & Corp. Sec. Comp: $455kDr. Bahram Valamehr Ph.D. (Age 46)Chief R&D Officer Comp: $455kDr. Yu-Waye Chu M.D. (Age 55)Chief Medical Officer Comp: $455kMr. Jim Beitel M.B.A.Sr. VP of Corp. Devel.Dr. Sarah CooleySr. VP of Clinical TranslationDr. Jerome Bressi Ph.D.Sr. VP of Regulatory & QualityMr. Brian T. Powl M.B.A. (Age 49)M.S., Chief Commercial Officer More ExecutivesKey CompetitorsVoyager TherapeuticsNASDAQ:VYGRJanux TherapeuticsNASDAQ:JANXTenaya TherapeuticsNASDAQ:TNYACompass TherapeuticsNASDAQ:CMPXFusion PharmaceuticalsNASDAQ:FUSNView All CompetitorsInsiders & InstitutionsProShare Advisors LLCSold 3,394 shares on 5/26/2023Ownership: 0.017%Capital Impact Advisors LLCBought 22,860 shares on 5/23/2023Ownership: 0.042%Ameriprise Financial Inc.Bought 58,233 shares on 5/22/2023Ownership: 0.078%JPMorgan Chase & Co.Bought 258,725 shares on 5/18/2023Ownership: 1.754%New York State Common Retirement FundSold 42,945 shares on 5/18/2023Ownership: 0.028%View All Insider TransactionsView All Institutional Transactions FATE Stock - Frequently Asked Questions Should I buy or sell Fate Therapeutics stock right now? 21 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last twelve months. There are currently 2 sell ratings, 14 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" FATE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FATE, but not buy additional shares or sell existing shares. View FATE analyst ratings or view top-rated stocks. What is Fate Therapeutics' stock price forecast for 2023? 21 Wall Street analysts have issued 1 year target prices for Fate Therapeutics' stock. Their FATE share price forecasts range from $5.00 to $65.00. On average, they anticipate the company's stock price to reach $15.50 in the next year. This suggests a possible upside of 201.0% from the stock's current price. View analysts price targets for FATE or view top-rated stocks among Wall Street analysts. How have FATE shares performed in 2023? Fate Therapeutics' stock was trading at $10.09 on January 1st, 2023. Since then, FATE shares have decreased by 49.0% and is now trading at $5.15. View the best growth stocks for 2023 here. When is Fate Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023. View our FATE earnings forecast. How were Fate Therapeutics' earnings last quarter? Fate Therapeutics, Inc. (NASDAQ:FATE) issued its quarterly earnings results on Wednesday, May, 3rd. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.55) by $0.36. The biopharmaceutical company had revenue of $58.98 million for the quarter, compared to the consensus estimate of $33.53 million. Fate Therapeutics had a negative trailing twelve-month return on equity of 45.62% and a negative net margin of 171.64%. Fate Therapeutics's revenue for the quarter was up 220.5% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.68) earnings per share. What ETFs hold Fate Therapeutics' stock? ETFs with the largest weight of Fate Therapeutics (NASDAQ:FATE) stock in their portfolio include Loncar Cancer Immunotherapy ETF (CNCR), ROBO Global Healthcare Technology and Innovation ETF (HTEC), SPDR S&P Biotech ETF (XBI), iShares Genomics Immunology and Healthcare ETF (IDNA), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Vanguard Russell 2000 Growth ETF (VTWG) and Principal Healthcare Innovators ETF (BTEC). What is Scott Wolchko's approval rating as Fate Therapeutics' CEO? 2 employees have rated Fate Therapeutics Chief Executive Officer Scott Wolchko on Glassdoor.com. Scott Wolchko has an approval rating of 100% among the company's employees. This puts Scott Wolchko in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Fate Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Fate Therapeutics investors own include Cara Therapeutics (CARA), CRISPR Therapeutics (CRSP), Juno Therapeutics (JUNO), NVIDIA (NVDA), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), Exelixis (EXEL), Neurocrine Biosciences (NBIX), Sorrento Therapeutics (SRNE) and Gilead Sciences (GILD). What is Fate Therapeutics' stock symbol? Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE." Who are Fate Therapeutics' major shareholders? Fate Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include State Street Corp (15.07%), BlackRock Inc. (11.66%), Bank of America Corp DE (2.19%), Two Sigma Advisers LP (1.90%), Two Sigma Investments LP (1.83%) and JPMorgan Chase & Co. (1.75%). Insiders that own company stock include Bahram Valamehr, Cindy Tahl, Daniel D Shoemaker, Edward J Dulac III, J Scott Wolchko, John Mendlein, Louis T Petrillo, Mark Plavsic, Redmile Group, Llc, Shefali Agarwal and Yu-Waye Chu. View institutional ownership trends. How do I buy shares of Fate Therapeutics? Shares of FATE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Fate Therapeutics' stock price today? One share of FATE stock can currently be purchased for approximately $5.15. How much money does Fate Therapeutics make? Fate Therapeutics (NASDAQ:FATE) has a market capitalization of $506.66 million and generates $96.30 million in revenue each year. The biopharmaceutical company earns $-281,720,000.00 in net income (profit) each year or ($2.42) on an earnings per share basis. How many employees does Fate Therapeutics have? The company employs 551 workers across the globe. How can I contact Fate Therapeutics? Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.fatetherapeutics.com. The biopharmaceutical company can be reached via phone at (858) 875-1800 or via email at christina@sternir.com. This page (NASDAQ:FATE) was last updated on 6/9/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.